profit from every $100 of sales.
$0$100
Aptorum Group
We have no price for Aptorum Group since 27 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$8.41+0.36% today
-49.3% since Oct 10, 25
1-year low $6.921-year high $16.60
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Aptorum Group sold, what it kept, and what it did with the cash.
Sales went from $1.30 million in 2022 to $0 in 2025, with -$1.36 million of profit last year.
SalesProfit
Aptorum Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aptorum Group | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Aptorum Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| -17 | -11 | -3 | -2 | |
| -16 | -9 | -3 | -2 | |
| -10 | -3 | -4 | -1 | |
| -2.75 | -0.62 | – | – | |
| 6.2% | 2.4% | – | – | |
| -1,325.2% | -2,457.5% | – | – | |
| -756.2% | -654.8% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 21 | 21 | 16 | 19 |
| Cash | 2 | 2 | 1 | 3 |
| Total debt | 7 | 3 | 3 | 3 |
| Total liabilities | 13 | 5 | 4 | 5 |
| 16 | 25 | 21 | 23 | |
| 4 | 5 | – | – | |
| -60.1% | -29.8% | -9.7% | -5.4% | |
| -62.4% | -11.4% | -20.2% | -5.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -12 | -8 | -1 | -2 | |
| 0 | 0 | – | – | |
| -13 | -8 | -1 | -2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- –
- 1.3×
- –
- –
- -1,355.5%
- -495.5%
- –
Profitability
- 2.4%
- -2,457.5%
- -654.8%
- –
- –
- –
- –
- –
- –
- –
Growth
- −66.7%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | -0.13 | – | – |
| Jan 22, 2026 | -0.06 | – | – |
| Apr 28, 2025 | -0.29 | – | – |
| Dec 20, 2024 | -0.50 | – | – |
| Apr 30, 2024 | 0.51 | -2.70 | +119.0% |
| Dec 22, 2023 | -1.43 | -2.60 | +45.2% |
| Apr 28, 2023 | -2.22 | -2.60 | +14.8% |
| Sep 30, 2022 | -0.53 | -3.00 | +82.4% |
News
Aptorum Group GAAP EPS of -$1.60Seeking Alpha · Aug 21, 2026The newest story we have is from Aug 21, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
3No pass
Philip Fisher
38No pass
Peter Lynch
13No pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
32No pass
Questions about Aptorum Group
Is Aptorum Group a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aptorum Group AI analysis
What does Aptorum Group do?
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. It is in Biotechnology.
Does Aptorum Group pay a dividend?
No. Aptorum Group does not pay a dividend at the moment.
Who are Aptorum Group's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Aptorum Group's.
Prices: daily closes to Jul 27, 2026. Fundamentals: company reports via invest-like data.